parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in retinal horizontal cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 29	0.91
pathways Reactome	6 pathways; mostly dopamine synapse	1.00

No case: the score is under the bar. Receipt 7918

TSPOAP1 in dopamine neurons, braak+0.08 (p 0.838) → -0.44 (p 0.238)receipt 7926
TSPOAP1 in astrocytes, braak-0.06 (p 0.873) → +0.26 (p 0.504)receipt 7925

receipt 7926: TSPOAP1 in dopamine neurons, braak

power: full sample -0.16 (p 0.532, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.487, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.19 (p 0.444, n 18). could be the mix.
skeptic: leave-one-out range -0.25 to -0.05, sign flips 0; without severely affected donors -0.16 (p 0.532, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TSPOAP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7925: TSPOAP1 in astrocytes, braak

power: full sample +0.13 (p 0.615, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.585, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.25 (p 0.315, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.26, sign flips 0; without severely affected donors +0.13 (p 0.615, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TSPOAP1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts